HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma

Blood

Volumn 125, Issue 11, 2015, Pages 1768-1771

  Zappasodi, Roberta ^a   Ruggiero, Giusi ^a   Guarnotta, Carla ^b   Tortoreto, Monica ^a   Tringali, Cristina ^c   Cavanè, Alessandra ^a   Cabras, Antonello D ^a   Castagnoli, Lorenzo ^a   Venerando, Bruno ^c   Zaffaroni, Nadia ^a   Gianni, Alessandro M ^a,c   De Braud, Filippo ^a   Tripodo, Claudio ^b   Pupa, Serenella M ^a   Di Nicola, Massimo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN H1; MYC PROTEIN; PROTEIN BCL 6; UNCLASSIFIED DRUG; BCL6 PROTEIN, HUMAN; DNA BINDING PROTEIN; HEAT SHOCK PROTEIN 110; HSPH1 PROTEIN, HUMAN; MYC PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CARCINOGENICITY; CONTROLLED STUDY; DOWN REGULATION; GENE SILENCING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LARGE CELL LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG SCREENING; GENETICS; HUMAN; LYMPHOMA, B-CELL; METABOLISM; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; DOWN-REGULATION; GENE KNOCKDOWN TECHNIQUES; HSP110 HEAT-SHOCK PROTEINS; HUMANS; LYMPHOMA, B-CELL; MICE; MICE, SCID; PROTO-ONCOGENE PROTEINS C-MYC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84924969034     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-07-590034     Document Type: Article

References (24)

1. Zappasodi R, Bongarzone I, Ghedini GC, et al. Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target. Blood. 2011;118(16):4421-4430.
2. Jaffe ES, Pittaluga S. Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification. Hematology Am Soc Hematol Educ Program. 2011;2011:506-514.
3. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med. 2008;359(6):613-626.
4. Ci W, Polo JM, Melnick A. B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma. Curr Opin Hematol. 2008;15(4):381-390.
5. Dave SS, Fu K, Wright GW, et al; Lymphoma/Leukemia Molecular Profiling Project. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med. 2006;354(23):2431-2442.
6. Ott G, Rosenwald A, Campo E. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Blood. 2013;122(24):3884-3891.
7. Hatzi K, Melnick A. Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis. Trends Mol Med. 2014;20(6):343-352.
8. Link JM, Hurlin PJ. The activities of MYC, MNT and the MAX-interactome in lymphocyte proliferation and oncogenesis. Biochim Biophys Acta. 2014. Epub ahead of print.
9. Cerchietti LC, Lopes EC, Yang SN, et al. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat Med. 2009;15(12):1369-1376.
10. Gaudio E, Paduano F, Ngankeu A, et al. Heat shock protein 70 regulates Tcl1 expression in leukemia and lymphomas. Blood. 2013;121(2):351-359.
11. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell. 2009;136(5):823-837.
12. Oki Y, Copeland A, Romaguera J, et al. Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma. Leuk Lymphoma. 2012;53(5):990-992.
13. Franco G, Guarnotta C, Frossi B, et al. Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma. Blood. 2014;123(12):1836-1849.
14. Yamagishi N, Ishihara K, Saito Y, Hatayama T. Hsp105 family proteins suppress staurosporine-induced apoptosis by inhibiting the translocation of Bax to mitochondria in HeLa cells. Exp Cell Res. 2006;312(17):3215-3223.
15. Kumagai J, Fukuda J, Kodama H, et al. Germ cell-specific heat shock protein 105 binds to p53 in a temperature-sensitive manner in rat testis. Eur J Biochem. 2000;267(10):3073-3078.
16. Hosaka S, Nakatsura T, Tsukamoto H, Hatayama T, Baba H, Nishimura Y. Synthetic small interfering RNA targeting heat shock protein 105 induces apoptosis of various cancer cells both in vitro and in vivo. Cancer Sci. 2006;97(7):623-632.
17. Yamagishi N, Fujii H, Saito Y, Hatayama T. Hsp105beta upregulates hsp70 gene expression through signal transducer and activator of transcription-3. FEBS J. 2009;276(20):5870-5880.
18. Bohonowych JE, Gopal U, Isaacs JS. Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls. J Oncol. 2010;2010:412985.
19. Dong D, Stapleton C, Luo B, et al. A critical role for GRP78/BiP in the tumor microenvironment for neovascularization during tumor growth and metastasis. Cancer Res. 2011;71(8):2848-2857.
20. Yamamoto Y, Nakatsura T, Ohgaki Y, et al. Immunohistochemical analysis of heat shock protein 105 in human breast cancer [abstract]. Proceedings of the 98th AACR Annual Meeting. Cancer Res. 2007;67:Abstract 2157.
21. Baudino TA, McKay C, Pendeville-Samain H, et al. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev. 2002;16(19):2530-2543.
22. Knies-Bamforth UE, Fox SB, Poulsom R, Evan GI, Harris AL. c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism. Cancer Res. 2004;64(18):6563-6570.
23. Tikhonenko AT, Black DJ, Linial ML. Viral Myc oncoproteins in infected fibroblasts down-modulate thrombospondin-1, a possible tumor suppressor gene. J Biol Chem. 1996;271(48):30741-30747.
24. Saito Y, Yamagishi N, Hatayama T. Different localization of Hsp105 family proteins in mammalian cells. Exp Cell Res. 2007;313(17):3707-3717.